Effective and Safe Glycemic Control in Patients with Diabetes Mellitus Type 2 when Using Fixed Combination of Oral Hypoglycemic Agents

Diabetes mellitus (DM) type 2 is associated not only with hyperglycemia, but also with an increased atherogenic risk. Due to this glucose-lowering therapy should be not only effective, but also safe regarding the development of micro- and macrovascular complications. To intensify hypoglycemic therapy in patients who do not achieve disease compensation at monotherapy with metformin or sulfonylureas, combination of these two oral hypoglycemic agents is considered reasonable. One of these combinations, that can effectively, safely and economically feasible to achieve therapeutic objectives of treatment of diabetes mellitus type 2, is considered fixed combination of metformin and glibenclamide (Glibomet). The most important advantages of fixed combinations include low doses of each drug component without loss of anti-diabetic efficacy, a significant decrease in side effects from the gastrointestinal tract, minimizing the risk of hypoglycemic reactions and others. A fixed combination of glibenclamide and metformin allows simple, flexible regimen increases compliance in patients, providing psychological comfort and improves quality of life